Clinical Trial News

FNIH study in Radiology identifies variations in ultrasound elastography measurements, aiding interpretation of liver disease progression. Findings suggest a 30.7% difference in SWE and 35.6% in VCTE may reflect technical variability, not true changes in liver stiffness, guiding future clinical trials and reducing reliance on liver biopsies.

© 2024 Mashup Media, LLC. All rights reserved.

FDA approves TREMFYA®, the first dual-acting IL-23 inhibitor for active ulcerative colitis, showing significant endoscopic remission rates in QUASAR program. TREMFYA® is also approved for plaque psoriasis and psoriatic arthritis.

FDA grants 7-year market exclusivity to YORVIPATH for treating hypoparathyroidism in adults.

Study compares effectiveness of starting chronic pain treatment with standard rehabilitative care (SRC) vs. complementary and integrative health (CIH) therapies using a Sequential Multiple Assignment Randomized Trial (SMART) Design. Both groups showed significant improvement up to six months, with CIH initially showing more improvement. Findings support expanding access to CIH approaches.

FDA clears Turing Medical's Bullsai Identify, an AI-driven brain mapping tech for personalized neuromodulation therapy in Parkinson's disease, aiming to enhance treatment precision and reduce side effects.

TEER with TriClip reduced TR to moderate or less in 79% of patients, with sustained benefits including TR reduction and QOL improvements at three years. The proportion of patients with NYHA class III or IV dropped from 76% to 19%. The safety profile remains favorable, though the impact on mortality or hospitalization for heart failure is unclear.

John T. Hamm, M.D., is the first to administer a Phase 1 clinical trial medication for solid tumors, sponsored by OncoC4 Inc., at Norton Cancer Institute. The trial aims to reduce tumor size and slow spread in advanced/metastatic solid tumors.

Two studies in *Pediatrics* show nirsevimab's safety and efficacy in preventing RSV in infants and children, with Spain's universal RSV prevention via nirsevimab reducing hospitalizations by 63%. Additionally, Oregon research finds a strong correlation between viral wastewater concentration and community respiratory tests for flu, RSV, and COVID-19.

MMJ BioPharma Cultivation sues DEA for delays in cannabis research approval for MS and HD treatments, alleging financial harm and patient suffering. The lawsuit questions DEA's use of Administrative Law Judges and accuses DEA Administrator Anne Milgram of bias against cannabis research.